Skip to main content
Premium Trial:

Request an Annual Quote

BioIVT Acquires Virtual Biobank Tissue Solutions

NEW YORK — BioIVT said on Monday that it has acquired UK-based virtual biobank Tissue Solutions.

BioIVT said that it intends to continue operating Tissue Solutions' facilities. Financial terms of the deal were not disclosed.

Tissue Solutions provides a range of specimens through a global supplier network including fresh, frozen, and formalin-fixed, paraffin-embedded control tissue and skin samples; disease state peripheral blood mononuclear cells and bone marrow mononuclear cells; and fresh and frozen blood and biofluids.

Westbury, New York-based BioIVT markets research models and services for drug discovery and development, specializing in control and disease-state biospecimens such as human and animal tissues, cell products, blood, and other biofluids.

"This acquisition will add 150 collection sites to BioIVT's network, giving us greater access to high-quality control and disease state biospecimens and increased global reach for prospective collections," BioIVT CEO Jeff Gatz said in a statement. "Furthermore, it will expand our skin product offerings for in vitro models."

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.